RalphJHaukeMD

Clinical Trials

• Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer Start of enrollment: 2004 Aug 31

  Completed

  Phase 1

• Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Aug 15

  Completed

  Phase 1

• Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2004 Jan 01

  Terminated

  Phase 2

• Talabostat in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2006 Dec 01

  Withdrawn

  Phase 2

• Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer Start of enrollment: 2007 Mar 01

  Terminated

  Phase 2

• Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma Start of enrollment: 2007 Oct 02

  Completed

• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01

  Completed

  Phase 1, Phase 2

• First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01

  Terminated

  Phase 2

• Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01

  Terminated

  Phase 3

• PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01

  Completed

• First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Start of enrollment: 2012 Jan 01

  Completed

  Phase 2

• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08

  Active, not recruiting

  Phase 3

• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12

  Completed

  Phase 3

• Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01

  Completed

  Phase 2

• Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Start of enrollment: 2013 May 14

  Completed

  Phase 4

• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08

  Active, not recruiting

  Phase 3

• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08

  Completed

  Phase 2

• HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01

  Terminated

  Phase 4

• Randomized Phase II Study of AB (Abraxane™, Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative) Start of enrollment: 2013 Oct 01
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16

  Active, not recruiting

  Phase 3

• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09

  Completed

  Phase 3

• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03

  Active, not recruiting

  Phase 3

• Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 18

  Completed

  Phase 2

• A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23

  Recruiting

  Phase 2, Phase 3

• Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma Start of enrollment: 2018 May 07

  Terminated

  Phase 2

• Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma Start of enrollment: 2019 Oct 28

  Active, not recruiting

  Phase 3

• A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer Start of enrollment: 2021 Feb 23

  Terminated

  Phase 1

• A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Start of enrollment: 2021 Oct 26

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator, Contact

• Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer Start of enrollment: 2023 Jan 30

  Recruiting

  Phase 1, Phase 2

  Roles: Contact

• Join now to see all